AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10730732 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg x kg(‐1) mivacurium
Number of subjects: 90
Study 10730732 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg x kg(‐1) rocuronium
Number of subjects: 90
Study 10730732 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.08 mg kg(‐1) mivacurium plus 0.2 mg x kg(‐1) rocuronium
Number of subjects: 90
Study 9179543 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium infusion
Number of subjects: 8
Study 9179543 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 8
Study 9179543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8247075 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune globulin (2 g per kilogram of body weight)
Number of subjects: 15
Study 8247075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 8247075 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune globulin (after crossover)
Number of subjects: 15
Study 8247075 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune globulin (biopsies)
Number of subjects: 15
Study 3102089 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide (IFOS) 5 g/m2
Number of subjects: 171
Study 3102089 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (CYCLO) 1.5 g/m2
Number of subjects: 171
Study 3102089 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide (IFOS)
Number of subjects: 171
Study 3102089 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (CYCLO)
Number of subjects: 171
Study 30641301 — intervention group
Group type: EXPERIMENTAL
Intervention: Early pubertal onset
Number of subjects: 121
Study 30641301 — intervention group
Group type: EXPERIMENTAL
Intervention: Early pubertal onset with a sexual partner more than 2 years older
Number of subjects: 121
Study 27759623 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-day antimicrobial prophylaxis (antibiotic treatment on days 1 and 2)
Number of subjects: 86
Study 27759623 — intervention group
Group type: COMPARATOR
Intervention: 4-day antimicrobial prophylaxis (antibiotic treatment on days 1 to 4)
Number of subjects: 86
Study 27759623 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-day antimicrobial prophylaxis
Number of subjects: 86
Study 27759623 — intervention group
Group type: COMPARATOR
Intervention: 4-day antimicrobial prophylaxis
Number of subjects: 86
Study 26956650 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped care (psychoeducation, guided Internet treatment, and face-to-face CBT)
Number of subjects: 173
Study 26956650 — intervention group
Group type: COMPARATOR
Intervention: Direct face-to-face CBT
Number of subjects: 173
Study 26956650 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped care
Number of subjects: 173
Study 26956650 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 173
Study 25409776 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care intervention (behavioural activation and medication management) delivered over eight to 10 weekly sessions by a case manager liaising with general practitioners.
Number of subjects: 450
Study 25409776 — intervention group
Group type: COMPARATOR
Intervention: Usual GP care (control group).
Number of subjects: 450
Study 25409776 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care intervention (cost effectiveness analysis).
Number of subjects: 450
Study 25409776 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care intervention (qualitative process evaluation).
Number of subjects: 450
Study 21933332 — intervention group
Group type: EXPERIMENTAL
Intervention: Home uroflowmetry
Number of subjects: 186
Study 21933332 — intervention group
Group type: COMPARATOR
Intervention: IPSS
Number of subjects: 186
Study 20215619 — intervention group
Group type: EXPERIMENTAL
Intervention: efavirenz, lamivudine and enteric-coated didanosine (efavirenz-A [QD])
Number of subjects: 262
Study 20215619 — intervention group
Group type: COMPARATOR
Intervention: efavirenz plus continuation of current nucleoside reverse transcriptase inhibitors (efavirenz-B)
Number of subjects: 262
Study 20215619 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens (efavirenz-A and efavirenz-B)
Number of subjects: 262
Study 18566298 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release niacin (2 g/d)
Number of subjects: 5
Study 18566298 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release niacin (2 g/d) plus lovastatin (40 mg/d)
Number of subjects: 5
Study 18566298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 15944165 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention (BI), N = 25
Number of subjects: 49
Study 15944165 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Standard of Care (ESC), N = 24
Number of subjects: 49
Study 11996927 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg androstenedione
Number of subjects: 37
Study 11996927 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg androstenedione
Number of subjects: 37
Study 11996927 — intervention group
Group type: COMPARATOR
Intervention: 0 mg androstenedione (control group)
Number of subjects: 37
Study 10102588 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% N2O with clonidine
Number of subjects: 33
Study 10102588 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% N2O
Number of subjects: 33
Study 10102588 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% oxygen with clonidine
Number of subjects: 33
Study 10102588 — intervention group
Group type: COMPARATOR
Intervention: 100% oxygen with placebo
Number of subjects: 33
Study 10102588 — intervention group
Group type: COMPARATOR
Intervention: 30% N2O with placebo
Number of subjects: 33
Study 8830642 — intervention group
Group type: EXPERIMENTAL
Intervention: Metamphocin (methyl ether of amphotericin B) administered as drop-like intravenous injections in combination with local instillation of ketoconazole and dexamethasone.
Number of subjects: 10
Study 8830642 — intervention group
Group type: EXPERIMENTAL
Intervention: Metamphocin (methyl ether of amphotericin B)
Number of subjects: 10
Study 1969678 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid defined formula diet (DFD)
Number of subjects: 95
Study 1969678 — intervention group
Group type: COMPARATOR
Intervention: Combination of 6‐methyl‐prednisolone and sulfasalazine (drug treatment)
Number of subjects: 95
Study 376208 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol 0.25 mg
Number of subjects: 10
Study 376208 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol 2.5 mg
Number of subjects: 10
Study 376208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31651927 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic Exercise (AE)
Number of subjects: 40
Study 31651927 — intervention group
Group type: COMPARATOR
Intervention: Land Exercise (LE)
Number of subjects: 40
Study 30728886 — intervention group
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic Acid (DHA) at 100 μM for 48 hours
Number of subjects: 0
Study 30728886 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (MLT) at 1 μM for 48 hours
Number of subjects: 0
Study 30728886 — intervention group
Group type: EXPERIMENTAL
Intervention: Coincubation of DHA and MLT
Number of subjects: 0
Study 30728886 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA isolated
Number of subjects: 0
Study 30728886 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (MLT) alone or coincubated with DHA
Number of subjects: 0
Study 30728886 — intervention group
Group type: EXPERIMENTAL
Intervention: All incubations (DHA, MLT, and coincubation)
Number of subjects: 0
Study 30728886 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (MLT)
Number of subjects: 0
Study 27988287 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple biopsy specimens
Number of subjects: 57
Study 27988287 — intervention group
Group type: COMPARATOR
Intervention: Forceps biopsy specimens
Number of subjects: 57
Study 27122516 — intervention group
Group type: EXPERIMENTAL
Intervention: Single blade technique
Number of subjects: 184
Study 27122516 — intervention group
Group type: EXPERIMENTAL
Intervention: Double blade technique
Number of subjects: 184
Study 27122516 — intervention group
Group type: COMPARATOR
Intervention: Control blades (not specified as intervention)
Number of subjects: 184
Study 24646068 — intervention group
Group type: EXPERIMENTAL
Intervention: IV-ibuprofen (10 mg·kg(‐1))
Number of subjects: 161
Study 24646068 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 161
Study 21674629 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized botanical combination containing policosanol, tomato extract, orally bioavailable grape procyanidins and Oenothera biennis oil
Number of subjects: 60
Study 21674629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 19254446 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 68
Study 19254446 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual waitlist control
Number of subjects: 68
Study 17594627 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrectomy
Number of subjects: 33
Study 15802314 — intervention group
Group type: EXPERIMENTAL
Intervention: Circular excision and subsequent stripping
Number of subjects: 48
Study 15802314 — intervention group
Group type: COMPARATOR
Intervention: Direct stripping
Number of subjects: 48
Study 15802314 — intervention group
Group type: EXPERIMENTAL
Intervention: Stripping at the hilus
Number of subjects: 48
Study 15802314 — intervention group
Group type: COMPARATOR
Intervention: Coagulation and cutting at the hilus
Number of subjects: 48
Study 12225709 — intervention group
Group type: EXPERIMENTAL
Intervention: Late intervention and stent to the LAD + medical therapy (open artery group)
Number of subjects: 66
Study 12225709 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy (closed artery group)
Number of subjects: 66
Study 9606690 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (i.v.Ig) administered monthly at a dosage of 0.15‐0.20 g/kg for 2 years
Number of subjects: 148
Study 9606690 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 7624465 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy (CBT; n = 14)
Number of subjects: 26
Study 7624465 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiential group therapy program (ET; n = 12)
Number of subjects: 26
Study 7624465 — intervention group
Group type: COMPARATOR
Intervention: Comparison group of 149 HIV-infected men
Number of subjects: 26
Study 7624465 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (CBT and ET)
Number of subjects: 26
Study 7624465 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects showing larger decreases in distress
Number of subjects: 26
Study 2243877 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Number of subjects: 0
Study 2243877 — intervention group
Group type: COMPARATOR
Intervention: Flurbiprofen plus alprazolam
Number of subjects: 0
Study 2243877 — intervention group
Group type: COMPARATOR
Intervention: Flurbiprofen plus placebo
Number of subjects: 0
Study 541683 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis B vaccine
Number of subjects: 3000
Study 541683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3000
Study 29148597 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagenated bovine-derived bone (DBBM-C) covered with a collagen membrane
Number of subjects: 30
Study 29148597 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous healing (control group)
Number of subjects: 30
Study 26257143 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaporized cannabis (2.9% and 6.7% THC)
Number of subjects: 19
Study 26257143 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent low-dose alcohol (0.065g/210L peak BrAC)
Number of subjects: 19
Study 26257143 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaporized cannabis
Number of subjects: 19
Study 26257143 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fluid (OF) testing
Number of subjects: 19
Study 26257143 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood THC concentrations
Number of subjects: 19
Study 24721888 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose rapamycin (LD)
Number of subjects: 30
Study 24721888 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose rapamycin (STD)
Number of subjects: 30
Study 24721888 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment groups (LD+STD)
Number of subjects: 30
Study 24721888 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 30
Study 22397390 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 76
Study 22397390 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation
Number of subjects: 76
Study 22397390 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (music therapy and standard rehabilitation)
Number of subjects: 76
Study 20134405 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean red ginseng (KRG) root 3 g
Number of subjects: 17
Study 20134405 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginsenoside fraction 3 g
Number of subjects: 17
Study 20134405 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysaccharide fraction 3 g
Number of subjects: 17
Study 20134405 — intervention group
Group type: COMPARATOR
Intervention: Placebo 3 g
Number of subjects: 17
Study 18751561 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Number of subjects: 4
Study 15973097 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y gastric bypass (LRYGBP)
Number of subjects: 80
Study 15973097 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic mini-gastric bypass (LMGBP)
Number of subjects: 80
Study 15973097 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 80
Study 12735487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12735487 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric drugs
Number of subjects: 0
Study 12735487 — intervention group
Group type: EXPERIMENTAL
Intervention: Symbolic meaning hypothesis
Number of subjects: 0
Study 10790936 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast Cancer Patients' Needs Questionnaire (BR-CPNQ)
Number of subjects: 334
Study 10790936 — intervention group
Group type: COMPARATOR
Intervention: Rural women
Number of subjects: 334
Study 8836789 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin therapy (50 mg diluted in 50 ml saline, installed weekly for 8 weeks)
Number of subjects: 45
Study 8836789 — intervention group
Group type: COMPARATOR
Intervention: Control group (TUR alone)
Number of subjects: 45
Study 8836789 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin therapy
Number of subjects: 45
Study 1948212 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Smart Family Health Promotion Program (12-week program focused on eating, exercise, and smoking behavior changes)
Number of subjects: 42
Study 6437365 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of fluphenazine decanoate every two weeks
Number of subjects: 50
Study 6437365 — intervention group
Group type: COMPARATOR
Intervention: 25 mg of fluphenazine decanoate every two weeks
Number of subjects: 50
Study 30308558 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocriplasmin (single intravitreal injection)
Number of subjects: 466
Study 30305255 — intervention group
Group type: EXPERIMENTAL
Intervention: internet-delivered cognitive behavior therapy (iCBT)
Number of subjects: 90
Study 30305255 — intervention group
Group type: EXPERIMENTAL
Intervention: self-assessed cardiac-related fear
Number of subjects: 90
Study 30305255 — intervention group
Group type: EXPERIMENTAL
Intervention: sex
Number of subjects: 90
Study 30305255 — intervention group
Group type: EXPERIMENTAL
Intervention: number of words used in the first homework assignment
Number of subjects: 90
Study 30305255 — intervention group
Group type: EXPERIMENTAL
Intervention: random forest model
Number of subjects: 90
Study 26771268 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.3 mg/kg)
Number of subjects: 80
Study 26771268 — intervention group
Group type: COMPARATOR
Intervention: Physiologic solution (control)
Number of subjects: 80
Study 25879722 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation (SCS) + Conventional Medical Management (CMM)
Number of subjects: 80
Study 21822630 — intervention group
Group type: EXPERIMENTAL
Intervention: KiVa anti-bullying program
Number of subjects: 7741
Study 21822630 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 7741
Study 19968743 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified tunnel/connective tissue graft (CTG) technique with enamel matrix derivative (EMD)
Number of subjects: 20
Study 19968743 — intervention group
Group type: COMPARATOR
Intervention: Modified tunnel/connective tissue graft (CTG) technique alone
Number of subjects: 20
Study 19968743 — intervention group
Group type: COMPARATOR
Intervention: Both groups (experimental and control)
Number of subjects: 20
Study 18356607 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral stress management (CBSM)
Number of subjects: 104
Study 16043723 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous lispro (0.15 units/kg every 2 h)
Number of subjects: 60
Study 16043723 — intervention group
Group type: COMPARATOR
Intervention: Continuous intravenous regular insulin (0.1 unit x kg(‐1) x h(‐1); CIRI group)
Number of subjects: 60
Study 12454764 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (12+/‐1 g day(‐1))
Number of subjects: 23
Study 12454764 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 23
Study 12454764 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 23
Study 10084268 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with open-angle glaucoma (treated IOP > 21 mmHg)
Number of subjects: 474
Study 10084268 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with open-angle glaucoma (progression despite IOP < 21 mmHg)
Number of subjects: 474
Study 10084268 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with normal-tension glaucoma
Number of subjects: 474
Study 10084268 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 474
Study 8721940 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginseng 100 mg
Number of subjects: 36
Study 8721940 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginseng 200 mg
Number of subjects: 36
Study 8721940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 1783249 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammatory bowel disease patients
Number of subjects: 17
Study 1783249 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolutive colitis group
Number of subjects: 17
Study 6655414 — intervention group
Group type: EXPERIMENTAL
Intervention: Class teaching breast self-examination (BSE)
Number of subjects: 0
Study 6655414 — intervention group
Group type: COMPARATOR
Intervention: Control group (women in a different district)
Number of subjects: 0
Study 6655414 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-attenders
Number of subjects: 0
Study 30632018 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic BAC library construction and analysis of ZW-derived BAC clones
Number of subjects: 200448
Study 30632018 — intervention group
Group type: EXPERIMENTAL
Intervention: BAC library screening using a ZW-specific marker
Number of subjects: 200448
Study 30632018 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequencing of selected BAC clones (P331M17 and P122G2)
Number of subjects: 200448
Study 29883497 — intervention group
Group type: EXPERIMENTAL
Intervention: ramipril (maximum dose 10 mg depending on blood pressure) for 24±6 weeks
Number of subjects: 63
Study 29883497 — intervention group
Group type: COMPARATOR
Intervention: placebo for 24±6 weeks
Number of subjects: 63
Study 27998854 — intervention group
Group type: EXPERIMENTAL
Intervention: Early active antihypertensive treatment with SBP control target of 130‐140 mm Hg
Number of subjects: 102
Study 27998854 — intervention group
Group type: COMPARATOR
Intervention: Standard antihypertensive treatment with SBP control target of 170‐180 mm Hg
Number of subjects: 102
Study 25270886 — intervention group
Group type: EXPERIMENTAL
Intervention: Active website (Group 1)
Number of subjects: 558
Study 25270886 — intervention group
Group type: EXPERIMENTAL
Intervention: Active website with telephone (Group 2)
Number of subjects: 558
Study 25270886 — intervention group
Group type: EXPERIMENTAL
Intervention: Active website with email (Group 3)
Number of subjects: 558
Study 25270886 — intervention group
Group type: COMPARATOR
Intervention: Control (Group 4)
Number of subjects: 558
Study 25270886 — intervention group
Group type: COMPARATOR
Intervention: Control with telephone (Group 5)
Number of subjects: 558
Study 22083325 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoendoscopic single-site varicocele ligation (LESS-VL)
Number of subjects: 82
Study 22083325 — intervention group
Group type: COMPARATOR
Intervention: Conventional transperitoneal laparoscopic varicocele ligation (CTL-VL)
Number of subjects: 82
Study 19327258 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 21747350 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided foam sclerotherapy with sapheno-femoral junction ligation
Number of subjects: 60
Study 21747350 — intervention group
Group type: COMPARATOR
Intervention: Standard stripping surgery
Number of subjects: 60
Study 16046308 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 3234
Study 16046308 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg twice a day)
Number of subjects: 3234
Study 16046308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3234
Study 11826416 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 331
Study 11826416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 331
Study 10365734 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estradiol valerate combined with micronized progesterone
Number of subjects: 37